Sacramento Telehealth Company Positions Multi-Form Compounded Semaglutide Access Through Licensed Medical Providers Ahead of ...

The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS will use the annual formulary review process to ensure that plans cover all ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Trial sponsors are typically responsible for providing the experimental drug or treatment at no cost to patients. However, ...

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

Next year will mark a turning point for AI in healthcare as the industry shifts from pilots and hype to accountable, integrated systems that prove to have measurable impact, according to execs.

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...

TLX591-CDx (Illuccix® in approved jurisdictions, 68 Ga-PSMA-11 ): Positive data from Phase 3 study in Chinese patients provides the basis for near-term NDA submission in China.

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

TAMPA, FLORIDA / ACCESS Newswire / December 4, 2025 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader implementing EinsteinRx™ artificial intelligence ...